António Campos1,2,3, Elisa J Campos4,5, Anália do Carmo5,6, Miguel Patrício4,5,7, João P Castro de Sousa8,9, António Francisco Ambrósio4,5, Rufino Silva4,10,11. 1. Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal. acamposoft@gmail.com. 2. CNC.IBILI Consortium, University of Coimbra, Coimbra, Portugal. acamposoft@gmail.com. 3. Department of Ophthalmology, Leiria Hospital, Leiria, Portugal. acamposoft@gmail.com. 4. Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal. 5. CNC.IBILI Consortium, University of Coimbra, Coimbra, Portugal. 6. Clinical Pathology Department, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal. 7. Laboratory of Biostatistics and Medical Informatics, Faculty of Medicine, University of Coimbra, Coimbra, Portugal. 8. Department of Ophthalmology, Leiria Hospital, Leiria, Portugal. 9. Medical Sciences Department, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal. 10. Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal. 11. Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal.
Abstract
PURPOSE: The aim of this study was to evaluate subfoveal choroidal thickness (SFCT) as a marker of outcome in real-world treatment of diabetic macular edema (DME) and to correlate it with choroidal thicknesses (CT) collected around the fovea. METHODS: Prospective interventional case series included a total of 126 eyes from 126 patients with recently diagnosed DME treated with a 3-monthly loading dose of ranibizumab or aflibercept and PRN thereafter until 24 months (M). CT was manually measured in the central 3500 μm area, subfoveally (SFCT), at 1750 μm right and left from the center in the horizontal plane and at 1750 μm up and down from the center in the vertical plane, by OCT. Anatomic (10% decrease in central retinal thickness) and functional (gain ≥ 5 letters) responses were assessed using univariate and multivariate analyses. The areas under ROC curves were used to assess whether baseline SFCT was a predictor of outcome. RESULTS: CT significantly decreased in all follow-ups (3 months after the 3 injections' loading dose (3M), 6 months (6M), 12 months (12M), 18 months (18M), 24 months (24M)). SFCT and other CT parameters are correlated. SFCT decrease from baseline was related with treatment (p = 0.003 to p < 0.001) but not with anatomic (3M, p = 0.858; 6M p = 0.762) or functional response (3M, p = 0.746; 6M, p = 0.156). SFCT was not found to be predictive of anatomic (AUC = 0.575, p = 0.172) or functional (AUC = 0.515, p = 0.779) outcome. CONCLUSIONS: SFCT is a reliable marker of choroidal thickness. Baseline SFCT decreased with anti-VEGF treatment but did not predict DME outcome.
PURPOSE: The aim of this study was to evaluate subfoveal choroidal thickness (SFCT) as a marker of outcome in real-world treatment of diabetic macular edema (DME) and to correlate it with choroidal thicknesses (CT) collected around the fovea. METHODS: Prospective interventional case series included a total of 126 eyes from 126 patients with recently diagnosed DME treated with a 3-monthly loading dose of ranibizumab or aflibercept and PRN thereafter until 24 months (M). CT was manually measured in the central 3500 μm area, subfoveally (SFCT), at 1750 μm right and left from the center in the horizontal plane and at 1750 μm up and down from the center in the vertical plane, by OCT. Anatomic (10% decrease in central retinal thickness) and functional (gain ≥ 5 letters) responses were assessed using univariate and multivariate analyses. The areas under ROC curves were used to assess whether baseline SFCT was a predictor of outcome. RESULTS: CT significantly decreased in all follow-ups (3 months after the 3 injections' loading dose (3M), 6 months (6M), 12 months (12M), 18 months (18M), 24 months (24M)). SFCT and other CT parameters are correlated. SFCT decrease from baseline was related with treatment (p = 0.003 to p < 0.001) but not with anatomic (3M, p = 0.858; 6M p = 0.762) or functional response (3M, p = 0.746; 6M, p = 0.156). SFCT was not found to be predictive of anatomic (AUC = 0.575, p = 0.172) or functional (AUC = 0.515, p = 0.779) outcome. CONCLUSIONS: SFCT is a reliable marker of choroidal thickness. Baseline SFCT decreased with anti-VEGF treatment but did not predict DME outcome.
Authors: Bianca S Gerendas; Sebastian M Waldstein; Christian Simader; Gabor Deak; Bilal Hajnajeeb; Li Zhang; Hrvoje Bogunovic; Michael D Abramoff; Michael Kundi; Milan Sonka; Ursula Schmidt-Erfurth Journal: Am J Ophthalmol Date: 2014-08-12 Impact factor: 5.258
Authors: Nadim Rayess; Ehsan Rahimy; Gui-Shuang Ying; Nika Bagheri; Allen C Ho; Carl D Regillo; James F Vander; Jason Hsu Journal: Am J Ophthalmol Date: 2014-09-28 Impact factor: 5.258
Authors: David J Browning; Adam R Glassman; Lloyd Paul Aiello; Roy W Beck; David M Brown; Donald S Fong; Neil M Bressler; Ronald P Danis; James L Kinyoun; Quan Dong Nguyen; Abdhish R Bhavsar; Justin Gottlieb; Dante J Pieramici; Michael E Rauser; Rajendra S Apte; Jennifer I Lim; Päivi H Miskala Journal: Ophthalmology Date: 2006-11-21 Impact factor: 12.079
Authors: António Campos; Elisa J Campos; Anália do Carmo; Francisco Caramelo; João Martins; João P Sousa; António Francisco Ambrósio; Rufino Silva Journal: Eye Vis (Lond) Date: 2018-10-11